IBS and the gut microbiome: what's the connection?

If you have IBS, chances are you’ve encountered the microbiome conversation. Maybe a well-meaning friend has recommended a probiotic. Maybe you’ve fallen down a rabbit hole of fermented foods, gut health supplements, and claims about “rebalancing your gut bacteria.” Maybe you’ve already spent a reasonable amount of money trying some of it.

The gut microbiome is a genuinely fascinating area of research, and it does have a real connection to IBS. But the science is more complicated, and considerably more honest about its own limitations, than the wellness industry tends to suggest. Read on to find out what we actually know, what we don’t, and what it means for how you think about your symptoms.

What the gut microbiome actually is

The gut microbiome refers to the trillions of microorganisms: bacteria, fungi, viruses, and other microbes, that live in your digestive tract. Far from being unwanted passengers, these microorganisms play an active role in digestion, immune function, inflammation, and even mood. The gut microbiome is in constant communication with the brain via the gut-brain axis; the two-way nervous system highway that, in IBS, becomes dysregulated in ways that drive symptoms.

When the microbiome is diverse and balanced, it supports healthy gut function. When it’s disrupted, through illness, antibiotics, chronic stress, diet, or other factors, that balance shifts, and the effects can ripple outwards in ways that aren’t always immediately obvious.

What the research shows about IBS and the microbiome

Studies consistently find that people with IBS show differences in microbiome composition compared to people without IBS — lower overall diversity, and different ratios of certain bacterial strains, including lower levels of Lactobacillus and Bifidobacterium and higher levels of Escherichia coli (Wang et al., 2020; Pittayanon et al., 2019). This is a real and reproducible finding, and it’s what’s driven much of the excitement around the microbiome as a potential key to understanding IBS.

But here’s the part that often gets lost in translation: we don’t yet know whether these differences cause IBS, whether they result from it, or whether they’re simply associated with it — present alongside IBS without being a direct driver of it. Pittayanon et al. noted explicitly that studies are still needed to determine whether these microbes are a product or a cause of IBS — an important caveat that rarely makes it onto supplement packaging.

This is not a minor distinction. It’s the difference between “fix your microbiome and you’ll fix your IBS”, which is what a lot of supplement marketing implies, and: “people with IBS tend to have a different microbiome, and we’re still working out what that means.” The science is in the second camp. The supplement industry, largely, is in the first.

The gut-brain-microbiome triangle

What makes the microbiome story particularly interesting in the context of IBS is how it connects to the gut-brain axis. The microbiome doesn’t just influence local gut function, it communicates directly with the brain. It does this partly through the vagus nerve, the main communication channel between the gut and the brain, and partly through the production of neurotransmitters. Around 90% of the body’s serotonin (a neurotransmitter closely involved in mood, anxiety, and gut motility) is produced in the gut, and the microbiome plays a role in that production.

This means that disruption to the microbiome doesn’t just affect digestion in isolation. It feeds into the same gut-brain communication system that’s already dysregulated in IBS, potentially amplifying the hypersensitivity, the motility issues, and the stress reactivity that characterise the condition.

It also means the relationship runs in both directions. Chronic stress, which both contributes to and results from IBS, negatively affects microbiome composition. A disrupted microbiome can worsen gut symptoms. Worsened gut symptoms increase stress and anxiety. The microbiome, in other words, is another thread woven into the same vicious cycle.

Probiotics: do they actually help?

This is where things get complicated, and where it’s worth being honest about both what the evidence shows and the context in which probiotic products are sold. Some studies do show that certain probiotic strains produce modest improvements in specific IBS symptoms, particularly bloating and stool consistency (Ticinesi et al., 2024; Boicean et al., 2025). That’s not nothing, and probiotics aren’t harmful. But several important caveats are worth understanding before you invest.

First, the effects are strain-specific. A 2025 strain-specific meta-analysis found that while some individual strains showed meaningful symptom reductions, others showed no effect on the same symptoms at all (Boicean et al., 2025). A probiotic that shows benefit in one study for one bacterial strain tells you very little about the product you’re looking at on a pharmacy shelf, which may contain entirely different strains at different concentrations. The research doesn’t translate neatly into product recommendations.

Second, the evidence on durability is thin. Most probiotic studies measure outcomes while participants are actively taking the supplement. What happens when they stop is much less well understood, and the limited data we have doesn’t convincingly show that the benefits persist beyond the period of supplementation. Whether probiotics produce lasting change in microbiome composition, or simply a temporary shift that reverses once you stop taking them, remains an open question.

Third, and this is important, the probiotic supplement industry is poorly regulated. Unlike licensed medicines, probiotic products are not required to prove efficacy before making health claims. Manufacturers can suggest benefits that aren’t backed by robust clinical evidence, and there is currently no consistent regulatory standard for what constitutes a meaningful or effective probiotic product. The industry has moved considerably faster than the science, and marketing has filled the gap. None of this means probiotics are useless, but it means they’re worth approaching with realistic expectations rather than as a solution.

What actually supports a healthy microbiome

While the science on directly “fixing” the microbiome in IBS is still developing, there’s reasonable evidence for what supports microbiome health more generally, and most of it isn’t found in a supplement aisle.

Dietary diversity, which matters more than elimination. A wide variety of plant foods: different vegetables, fruits, whole grains, legumes, feeds a wider range of beneficial bacterial strains. This is almost the opposite of the narrowing that tends to happen when IBS leads to more and more dietary restriction.

Fibre is important, though the type matters — soluble fibre tends to be better tolerated in IBS than insoluble fibre, and increases should be gradual.

Sleep has a more significant impact on microbiome composition than most people realise. Disrupted sleep affects the gut environment, which in turn affects gut function.

Movement — regular, moderate exercise — is associated with greater microbiome diversity.

And stress management is arguably the most important of all. Chronic stress is one of the most consistently documented negative influences on microbiome health. Which brings us back, inevitably, to the gut-brain axis.

Where hypnotherapy fits into this

Gut-directed hypnotherapy doesn’t directly alter microbiome composition, it would be an over claim to suggest otherwise, and the research isn’t there yet. What it does do is work on the gut-brain axis: calming the nervous system, reducing visceral hypersensitivity, improving gut motility, and breaking the stress-symptom cycle that keeps IBS entrenched. In doing so, it creates conditions in which the gut environment is more stable: less inflamed, less reactive, functioning more regularly, which is the kind of environment in which a healthier microbiome can exist.

There is also early and emerging research looking at whether psychological interventions that reduce gut inflammation and improve motility have downstream effects on microbiome diversity. It’s genuinely interesting territory, and it points towards a picture of IBS treatment that addresses the whole system rather than any single component of it.

The microbiome is one piece of a complex picture. The gut-brain axis is the system that connects the pieces. And that’s where the most meaningful, lasting change tends to happen.

The science of the gut microbiome is moving quickly, and it will almost certainly tell us more about IBS in the years ahead. But we’re not yet at the point where targeting the microbiome directly is a reliable path to lasting relief, and the products currently on the market reflect commercial opportunity more than clinical certainty.

What we do know is that the gut-brain connection is central to IBS, that stress and the nervous system are deeply implicated, and that working on that system produces real, measurable, durable change for the majority of people who try it.

If you’re curious about whether gut-directed hypnotherapy could be right for you, I’d love to have a conversation. My free 30-minute discovery call is no-pressure — just a chance to talk through where you are and whether this feels like a good fit.

References

Wang L, Alammar N, Singh R, et al. Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. J Acad Nutr Diet. 2020;120(4):565–586. https://pubmed.ncbi.nlm.nih.gov/31473156/
Pittayanon R, Lau JT, Yuan Y, et al. Gut Microbiota in Patients With Irritable Bowel Syndrome — A Systematic Review. Gastroenterology. 2019;157(1):97–108. https://pubmed.ncbi.nlm.nih.gov/30940523/
Ticinesi A, et al. Efficacy of Probiotics in the Management of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. PMC. 2024. https://pubmed.ncbi.nlm.nih.gov/39830577/
Boicean A, et al. Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome. J Clin Med. 2025. https://pubmed.ncbi.nlm.nih.gov/41682832/